
# NuTide: 121 Global Phase III study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer

# BACKGROUND

- No approved agents exist for the first-line treatment of locally advanced/metastatic **Patient characteristics** biliary tract cancer (BTC)
- Current standard of care remains gemcitabine + cisplatin:
- Median overall survival (OS) 11.7 months (ABC-02)
- Resistance to chemotherapy is associated with poor survival
- Effective new agents and combinations are required


### Transforming nucleoside analogs into ProTides




### NUC-1031: A ProTide transformation of gemcitabine

- A new class of anti-cancer agents
- Overcomes key gemcitabine resistance mechanisms<sup>2</sup>
- Cellular uptake independent of nucleoside transporters (hENT1)
- Activation independent of deoxycytidine kinase (dCK)
- Protected from breakdown by cytidine deaminase (CDA)
- In comparison to gemcitabine, NUC-1031 has<sup>3</sup>:
- Greater plasma stability (t<sub>1/2</sub> 8.3 hours vs 1.5 hours)
- Increased intracellular levels of active anti-cancer metabolite, dFdCTP (217x)
- Reduced toxic metabolites

### NUC-1031 bypasses the key cancer resistance pathways of gemcitabine





CES: 1. Valle et al. N Engl J Med 2010; 362:1273-1281. 2. Slusarczyk et al. J Med Chem 2014; 57:1531-1542. 3. Blagden et al. Br J Cancer 2018; 119:815-822. ATIONS: BTC: biliary tract cancer OS: overall survival hENT1: human equilibrative nucleoside transporter 1 dCK: deoxycytidine kinase CDA: cytidine nacokinetics QoL: quality of life t<sub>1/2</sub>: half-life dFdCMP: difluoro-deoxycytidine monophosphate dFdCDP: difluoro-deoxycytidine diphosphate dFdU

hate dFdU: difluoro-dec


## ABC-08 (Phase Ib study NUC-1031 + cisplatin)

- Age ≥18 years, ECOG PS 0 or 1
- Previously untreated histologically or cytologically-confirmed adenocarcinoma of the biliary tract that is locally advanced, unresectable or metastatic
- Intention-to-treat (ITT) population: 14 patients
- Evaluable population: 11 patients completed ≥1 cycle


### Safety profile

- NUC-1031 + cisplatin was well-tolerated
- Multiple cycles administered (median 8; range 3.5-14)
- No unexpected adverse events (AEs)
- No dose-limiting toxicities (DLTs)
- Grade 3 AEs included: fatigue (21%), neutropaenia (14%), pyrexia (14%), nausea (7%), and increased liver function enzymes (ALT; 14%, AST; 7%) No Grade 4 treatment-related AEs
- No patients discontinued due to NUC-1031-related events

# VuTide:121 (Phase III study of NUC-1031 + cisplatin)



Statistical plan



Jennifer J Knox<sup>1</sup>, Mairéad G McNamara<sup>2</sup>, Lipika Goyal<sup>3</sup>, Mark K Doherty<sup>4</sup>, David P Cosgrove<sup>5</sup>, Christoph Springfeld<sup>6</sup>, Katrin M Sjoquist<sup>7</sup>, Joon Oh Park<sup>8</sup>, Helena Verdaguer<sup>9</sup>, Chiara Braconi<sup>10</sup> Paul J Ross<sup>11</sup>, Aimery de Gramont<sup>12</sup>, John R Zalcberg<sup>13</sup>, Daniel H Palmer<sup>14</sup>, Juan W Valle<sup>2</sup>


1) Princess Margaret Cancer Centre, Toronto, Ontario, Canada 2) University of Manchester & The Christie, Manchester, UK 3) Massachusetts General Hospital, Boston, US 4) Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada 5) Division of Medical Oncology, Vancouver Cancer Center, Compass Oncology, Vancouver, US 6) University Hospital Heidelberg, Germany 7) Cancer Care Centre, St George Hospital, Kogarah & NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia 8) Samsung Medical Center, Sungkyunkwan University cine, Seoul, Republic of Korea 9) Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain 10) University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK 11) Guy's Hospital, London, UK 12) Franco-British Institute, Levallois-Perret, Paris, France 13) Dept. of Medical Oncology Alfred Health & Cancer Research Program, School of Public Health, Monash University, Melbourne, Australia 14) University of Liverpool, Liverpool, UK

Presentation Number **80TiP** NCT Number: NCT04163900 EudraCT Number 2019-001025-28 Email: jennifer.knox@uhn.ca



Treatment duration and best overall response by BTC ABC-08 summary anatomic site of origin (evaluable population) NUC-1031 + cisplatin shows encouraging efficacy compared to standard of care • All BTC subtypes sensitive to NUC-1031 + cisplatin Durable responses 114+ wks NUC-1031 + cisplatin is well-tolerated over multiple cycles Objective response rates in ABC-08 and ABC-02 ABC-08 \*\*\*\*\*\*\* NUC-1031+ cisplatin \*\* nplete Response Partial Response **Complete Response 7%** (1/14) Stable Disease Progressive Disease Off Treatment Partial Response **43%** (6/14) 2nd Line Treatment Alive At Last Follow-**Objective Response Rate 50%** (7/14) Note: Responses un







- Global Phase III study at ~130 sites across North America, Europe and Asia-Pacific
- NUC-1031 + cisplatin has the potential to improve survival outcomes in patients with BTC
- Further study information: NuTide121@nucana.com

Endpoints

Primary


Endpoints

**0**S

ORR

Secondary Endpoint

Safetv



<sup>1</sup> With measurable disease at baseline (and ≥28 weeks follow-up <sup>2</sup> DIM = Difference in observed medians (vs. 11.7 months) <sup>3</sup> DIP = Difference in observed proportions (vs. 19.0%)

\* A statistically significant improvement in ORR at either of the first two interim analyses, supported by positive trends in other endpoints, could allow for an elerated approval of a new drug application for NUC-1031

ABC-02 <sup>1</sup> citabine + cisplatin
<b>0.6%</b> (1/161)
<b>25.5%</b> (41/161)
<b>26.1%</b> (42/161)
confirmed in ABC-08 and ABC-02

Copies of this e-poster obtained through QR, AR and/or text key codes are for personal use only and may not be reproduced without written permission of the authors